Duality of interest JJM has participated on advisory boards or has been invited as speaker by Astra Zeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly & Co., Intarcia Therapeutics Inc., MSD, Novo Nordisk, Novartis and Sanofi
M., Marey, A., Abugdida, M., et al
Correspondingly, fat mass loss comprised a larger proportion of total weight loss among those who received apitegromab (85.3% of total loss (81.289.5%) or 8.5 kg (7.49.6)) compared to those who received placebo (69.5% (65.773.3%) or 8.0 kg (7.09.0))
Dual GIP/GLP-1 receptor agonism and weight outcomes
Di- and trihydroxycholestanoic acids are transported by ABCD3
Key Takeaway: GHK-Cu does not just stimulate new growth